Viewing nowCombinationTelmitwin 40/5 mg Tablet
Telmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
(Ltd) Hanpung Pharmaceutical

MFDS item code 201905314 · Approved 2019.07.26 · Insurance code 658106760
Treatment of essential hypertension not controlled with monotherapy
This medication helps patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or telmisartan alone, by using both medications together for more effective blood pressure control. This combination helps to dilate blood vessels and lower blood pressure, reducing the burden on the heart and blood vessels. Therefore, it is useful for long-term management of hypertension, contributing to a decreased risk of complications. This treatment is effective in maintaining stable blood pressure in patients.
The recommended dose of this medicine is 1 tablet once daily, taken with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). It is recommended that the dose of each individual component (amlodipine or telmisartan) be adjusted before starting this medicine. However, a direct switch to this medicine may be considered if blood pressure is not controlled with the individual components, as follows: - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. For patients taking telmisartan and amlodipine concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience (limited to this medicine 40/5 mg). ○ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older adults: The usual amlodipine dosage is recommended for older adults, but caution should be exercised when increasing the dose (see section ‘3. Patients who should be treated with caution’). In patients aged 75 years and older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually.
○ Children: The safety and efficacy of this medicine have not been established in pediatric patients aged 18 years and younger; therefore, its use is not recommended.
This medication can cause serious harm to the fetus if used during pregnancy, particularly in the second and third trimesters, so women who are pregnant or may become pregnant should not take it. This medication should not be administered to individuals with allergies to its active components or dihydropyridine derivatives, or those with severely impaired liver function, severe hypotension, or heart disease. Patients with slightly impaired liver function, gastrointestinal disorders, or kidney diseases should use this medication with greater caution and must be particularly careful if there is any vascular abnormality in the kidneys. During the use of this medication, side effects such as dizziness or edema may occur, and serious side effects may rarely arise; if symptoms develop, immediate consultation with medical personnel is necessary. Do not start this medication during pregnancy, and if pregnancy is confirmed, discontinue it as soon as possible and switch to another safe medication. Patients at risk of hypotension should check their hydration and salt status before starting this medication, and if symptoms of hypotension occur, they should lie down and rest immediately and receive IV therapy if necessary. This medication can increase blood potassium levels, so potassium supplements or potassium-rich foods should be monitored regularly for blood potassium levels when taken together. Patients with impaired kidney function should have their kidney function and electrolyte levels regularly monitored during treatment, and safety in kidney transplant patients has not been established. Patients with heart disease or heart failure need to be careful when taking this medication, especially those with heart failure, as their edema may worsen, and consultation with medical personnel is advised. This medication may cause drowsiness or dizziness, so caution is needed when driving or operating dangerous machinery. Be cautious of potential interactions when taking this medication with other drugs, and inform medical personnel about any current medications, especially lithium, digoxin, warfarin, and non-steroidal anti-inflammatory drugs. This medication contains sorbitol and should not be taken by patients with fructose intolerance. The safety and efficacy for children and adolescents under 18 years have not been sufficiently established, so its use is not recommended. In cases of overdose, symptoms such as hypotension, cardiac arrhythmia, dizziness, and renal failure may occur, so immediate consultation with medical institutions for appropriate treatment is necessary. This medication should be kept out of reach of children and used immediately after opening to avoid moisture.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light, so it should be stored in an opaque container. Additionally, it should be stored at room temperature between 1 and 30 degrees Celsius to maintain its effectiveness.
A biconvex oval double tablet that is white and light gray.
30 tablets/PTP[(10 tablets/PTP X 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
(Ltd) Hanpung Pharmaceutical
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 334.72mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 334.72mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Bivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Vivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Bivozon Pharmaceutical Co., Ltd.
CombinationTelmisartan Powder 23.9% 167.36mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.